Cultural adaptation into Spanish of the generalized anxiety disorder-7 (GAD-7) scale as a screening tool

Javier García-Campayo, Enric Zamorano, Miguel A Ruiz, Antonio Pardo, María Pérez-Páramo, Vanessa López-Gómez, Olga Freire, Javier Rejas, Javier García-Campayo, Enric Zamorano, Miguel A Ruiz, Antonio Pardo, María Pérez-Páramo, Vanessa López-Gómez, Olga Freire, Javier Rejas

Abstract

Background: Generalized anxiety disorder (GAD) is a prevalent mental health condition which is underestimated worldwide. This study carried out the cultural adaptation into Spanish of the 7-item self-administered GAD-7 scale, which is used to identify probable patients with GAD.

Methods: The adaptation was performed by an expert panel using a conceptual equivalence process, including forward and backward translations in duplicate. Content validity was assessed by interrater agreement. Criteria validity was explored using ROC curve analysis, and sensitivity, specificity, predictive positive value and negative value for different cut-off values were determined. Concurrent validity was also explored using the HAM-A, HADS, and WHO-DAS-II scales.

Results: The study sample consisted of 212 subjects (106 patients with GAD) with a mean age of 50.38 years (SD = 16.76). Average completion time was 2'30''. No items of the scale were left blank. Floor and ceiling effects were negligible. No patients with GAD had to be assisted to fill in the questionnaire. The scale was shown to be one-dimensional through factor analysis (explained variance = 72%). A cut-off point of 10 showed adequate values of sensitivity (86.8%) and specificity (93.4%), with AUC being statistically significant [AUC = 0.957-0.985); p < 0.001]. The scale significantly correlated with HAM-A (0.852, p < 0.001), HADS (anxiety domain, 0.903, p < 0.001), and WHO-DAS II (0.696, p > 0.001).

Limitations: Elderly people, particularly those very old, may need some help to complete the scale.

Conclusion: After the cultural adaptation process, a Spanish version of the GAD-7 scale was obtained. The validity of its content and the relevance and adequacy of items in the Spanish cultural context were confirmed.

Figures

Figure 1
Figure 1
Maximum likelihood confirmatory solution of items in the adapted version of the GAD-7 scale. Standardized loadings. Chi-Square = 32.59, df = 14, p-value = 0.00330, RMSEA = 0.080
Figure 2
Figure 2
ROC curve of GAD-7 total score.
Figure 3
Figure 3
Mean and confidence interval (95%) of HAM-A score by severity group according to the GAD-7 scale. Anxiety group according to GAD-7 score; Normal/Minimum (0-7 points), Mild (8-10), Moderate (11-14) and Severe (15-21). p < 0.001 for between-group comparisons in all cases. Diagonal segments are produced by ties.
Figure 4
Figure 4
Mean (95% CI) standardized score of WHO DAS II scale, total and by domain, by group of subjects. GAD = Generalized Anxiety Disorder group; Control = Control group; **p < 0.001.

References

    1. Lobo A, Campos R. Los trastornos de ansiedad en atención primaria. Madrid EMISA. 1997.
    1. Mahe V, Valgo A. Long-term pharmacological treatment of generalized anxiety disorder. Inter Clin Psychopharmacol. 2000;15:99–105. doi: 10.1097/00004850-200015020-00006.
    1. Horwath Ey, Weissman MM. In: Textbook in psychiatric epidemiology. Tsuang MT, Tohen M, Zahner GEP, editor. Wiley-Liss; 1995. Epidemiology of depresion and anxiety disorders.
    1. Cano Vindel A. Trastornos de ansiedad, Sociedad Española para el estudio de la Ansiedad y el Estrés (SEAS) 2005. (last update: March 7th, 2005; last accessed: November 23rd, 2005)
    1. Andlin-Sobocki P, Wittchen HU. Cost of affective disorders in Europe. Eur J Neurol. 2005;12(Suppl 1):34–38. doi: 10.1111/j.1468-1331.2005.01195.x.
    1. Judd LL, Kessler RC, Paulus MP, Zeller PV, Wittchen HU, Kunovac JL. Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Study (NCS) Acta Psychiatr Scan. 1998;393:6–11. doi: 10.1111/j.1600-0447.1998.tb05960.x.
    1. Stein D. Comorbidity in Generalized Anxiety Disorder: Impact and Implications. J Clin Psychiatry. 2001;62(Suppl 1):29–36.
    1. The ESEMeD/MHEDEA 2000 investigators. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand. 2004;109(Suppl 420):21–27. doi: 10.1111/j.1600-0047.2004.00327.x.
    1. A.D.A.M. MedlinePlus. Información de salud para usted. Enciclopedia médica en español. Generalized anxiety disorder. 2004. (Revisado por VeriMed Healthcare Network. Last update: May 4th, 2004; Last access: November 23th, 2005)
    1. Lépine JP. The epidemiology of anxiety disorders: prevalence and societal costs. J Clin Psychiatry. 2002;63(suppl 14):4–8.
    1. Wittchen HU. Generalized anxiety disorder: Prevalence, burden, and cost to society. Depression and anxiety. 2002;16:162–171. doi: 10.1002/da.10065.
    1. Goldberg Dy, Lecrubier Y. In: Mental illness in general health care: An international study. Üstün TB, Sartorius N, editor. Chichester, John Wiley & Sons on behalf of WHO; 1995. Form and frequency of mental disorders across centres.
    1. Chocrón Bentata L, Vilalta Franch J, Legazpi Rodríguez I, Auquer Ky, Franch L. Prevalencia de Psicopatología en un centro de atención primaria. Aten Primaria. 1995;16:586–590.
    1. Hamilton M. Diagnosis and Rating of Anxiety. Br J Psychiat. 1969. pp. 76–9.
    1. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–70. doi: 10.1111/j.1600-0447.1983.tb09716.x.
    1. Lipman RS, Covi L. In: Evaluation of Psychological Therapies. Spitzer R, Klein D, editor. Baltimore, MD: Johns Hopkins University Press; 1976. Outpatient treatment of neurotic depression: medication and group psychotherapy; pp. 178–218.
    1. Snaith RP, Baugh S, Clayden A, Husain A, Sipple NA. The Clinical Anxiety Scale: an instrument derived from the Hamilton Anxiety Scale. Br J Psychiatry. 1982;141:518–523. doi: 10.1192/bjp.141.5.518.
    1. Spielberger CD, Gorsuch RLy, Lushene RE. Manual for the State-Trait Inventory. Palo Alto: Consulting Psychological Press. 1970.
    1. Wittchen HU, Boyer P. Screening for anxiety disorders. Sensitivity and specificity of the Anxiety Screening Questionnaire (ASQ-15) Br J Psychiatr. 1998;173(Suppl 34):10–17.
    1. Carroll BJ, Davidson JRT. Screening Scale for DSM-IV GAD. Copyright. 2000.
    1. Bobes J, Garcia-Calvo C, Prieto R, Garcia-Garcia M, Rico-Villademoros F. Propiedades psicométricas de la versión española de la Escala de Detección del Generalized anxiety disorder según DSM-IV de Carroll y Davidson. Actas Esp Psiquiatr. 2006;34(2):83–93.
    1. Spitzer RL, Kroenke K, Williams JBW, Löwe B. A Brief Measure for Assessing Generalized Anxiety Disorder. Arch Intern Med. 2006;166:1092–1097. doi: 10.1001/archinte.166.10.1092.
    1. Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol. 1993;46:1417–1432. doi: 10.1016/0895-4356(93)90142-N.
    1. Ruiz MA, Rejas J. In: Farmacoeconomía e investigación de resultados en salud: principios y práctica. En A Domínguez, Soto J, editor. Real Academia Nacional de Farmacia; 2002. Calidad de vida y otras medidas de salud informadas por el paciente En A; pp. 115–160.
    1. Nunnally JCy, Bernstein IJ. México: McGraw-Hill. 3 1995. Teoría Psicométrica.
    1. Rovienelli RJ, Hambleton RK. On the use of Content Specialists in the Assessment of Criterion-Referenced Test Item Validity. Tijdschrift voor Onderwijsresearch. 1977. pp. 49–60.
    1. Vázquez-Barquero JL, Vázquez Bourgón E, Herrera Castañedo S, Saiz J, Uriarte M, Morales F, Gaite L, Herrán A, Üstün TB. Cantabria disability work group, Actas Esp. Vol. 28. Psiquiatr; 2000. Spanish version of the new World Health Organization Disability Assessment Schedule II (WHO-DAS-II): initial phase of development and pilot study; pp. 77–87.
    1. World Health Organization. Disability Assessment Schedule II (WHO-DAS II) WHO, Geneva; 2000.
    1. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psych. 1951;16:297–334.
    1. Gorusch RL. Exploratory Factor Analysis: Its Role in Item Analysis. J Per Assess. 1997;68:532–560. doi: 10.1207/s15327752jpa6803_5.
    1. Batista-Foguet JM, Coendrs G, Alonso J. Análisis factorial confirmatorio. Su utilidad en la validación de cuestionarios relacionados con la salud. Med Clin (Barc) 2004;122(Supl 1):21–27. doi: 10.1157/13057542.
    1. Ruiz MA. Introducción a los modelos de ecuaciones estructurales. Madrid, UNED. 2000.
    1. Hair JF, Black WC, Babin BJ, Anderson RE, Tathan RL. Upper Saddle River. NJ: Pearson-Prentice Hall; 2006. Multivariate data analysis.
    1. Souetre E, Lozet H, Cimarosti I, Martin P, Chignon JM, Ades J, Tignol J, Darcourt G. Cost of anxiety disorders: Impact of comorbidity. J Psychosom Res. 1994;38(Suppl 1):151–160. doi: 10.1016/0022-3999(94)90145-7.
    1. Candilis PJ, Pollack MH. The hidden costs of untreated anxiety disorders. Harv Rev Psychiatry. 1997;5:40–42. doi: 10.3109/10673229709034724.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe